Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.
Circulation. 2020 May 19;141(20):1648-1655. doi: 10.1161/CIRCULATIONAHA.120.046941. Epub 2020 Mar 21.
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.
截至 2020 年 4 月 28 日，2019 冠状病毒病（COVID-19）是一种影响全球 185 个国家和超过 300 万患者的全球大流行疾病。COVID-19 是由严重急性呼吸系统综合征冠状病毒 2 引起的，它通过血管紧张素转换酶 2 受体侵入细胞。在 COVID-19 患者中，心血管疾病的患病率很高，超过 7%的患者因感染而出现心肌损伤（危重症患者中占 22%）。虽然血管紧张素转换酶 2 是感染的门户，但血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的作用仍需要进一步研究。COVID-19 对心脏移植构成了挑战，影响供者选择、免疫抑制和移植后管理。目前有许多有前途的治疗方法正在积极研究中，以治疗和预防 COVID-19。
